Repligen (NASDAQ:RGEN) Stock Price Down 10.3% – Time to Sell?

Shares of Repligen Corporation (NASDAQ:RGEN) were down 10.3% on Thursday . The stock traded as low as $111.40 and last traded at $111.5560. Approximately 189,490 shares traded hands during mid-day trading, a decline of 77% from the average daily volume of 820,074 shares. The stock had previously closed at $124.40.

Analyst Ratings Changes

A number of brokerages recently commented on RGEN. Rothschild & Co Redburn set a $160.00 target price on Repligen and gave the company a “buy” rating in a research report on Friday, April 17th. Wells Fargo & Company decreased their target price on Repligen from $190.00 to $180.00 and set an “overweight” rating for the company in a research report on Wednesday, February 25th. Weiss Ratings lowered Repligen from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Tuesday, March 3rd. Barclays decreased their target price on Repligen from $175.00 to $145.00 and set an “overweight” rating for the company in a research report on Tuesday, April 14th. Finally, Roth Mkm began coverage on Repligen in a research report on Friday, April 17th. They issued a “buy” rating and a $160.00 target price for the company. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Repligen has a consensus rating of “Moderate Buy” and a consensus price target of $170.93.

Repligen Price Performance

The firm has a market cap of $6.30 billion, a price-to-earnings ratio of 131.38, a P/E/G ratio of 2.59 and a beta of 1.19. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.12 and a current ratio of 8.37. The business has a 50 day simple moving average of $123.91 and a 200-day simple moving average of $146.04.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported $0.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.05. The business had revenue of $197.91 million during the quarter, compared to the consensus estimate of $192.23 million. Repligen had a return on equity of 4.71% and a net margin of 6.62%.The company’s quarterly revenue was up 18.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.44 EPS. Repligen has set its FY 2026 guidance at 1.930-2.010 EPS. Equities research analysts expect that Repligen Corporation will post 1.97 earnings per share for the current year.

Hedge Funds Weigh In On Repligen

A number of hedge funds and other institutional investors have recently modified their holdings of RGEN. United Capital Financial Advisors LLC purchased a new position in shares of Repligen in the 3rd quarter worth approximately $368,387,000. Opti Capital Management LP purchased a new position in shares of Repligen in the 4th quarter worth approximately $2,399,209,000. Wasatch Advisors LP purchased a new position in shares of Repligen in the 1st quarter worth approximately $146,513,000. Massachusetts Financial Services Co. MA purchased a new position in shares of Repligen in the 4th quarter worth approximately $199,176,000. Finally, Price T Rowe Associates Inc. MD boosted its stake in shares of Repligen by 31.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,599,061 shares of the biotechnology company’s stock worth $753,603,000 after buying an additional 1,091,683 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.